[ad_1]
Chicago, June 12, 2021 /PRNewswire/ – As a global non-profit leader in Alzheimer’s disease research and science, we have extensively reviewed Aduhelm’s clinical trial data™ (Adukalimumab). According to trial data, the treatment has shown effective results, which are also confirmed by leading scientists in Alzheimer’s and dementia sciences and the Food and Drug Administration (FDA). Research experts and consultants from the Alzheimer’s Association are very familiar with the basic and regulatory science that led to the FDA’s decision. They are correct to approve this treatment.
In addition, the FDA appropriately considered the huge unmet needs of the Alzheimer’s community. Aduhelm is certainly not a cure, but in the end it provides an effective treatment for many Alzheimer’s patients and their families. The confirmatory test should begin immediately.
Our focus has been and will continue to be to provide this treatment to all those who might benefit. Approval is the basic first step in access. The first drug in the category energized the field, increased investment in new therapies and encouraged greater innovation.
After approval, the manufacturer Biogen announced its intention to price Aduhelm as 56,000 USD Per year. The price is simply unacceptable. For many people, this price will constitute an insurmountable obstacle. It complicates the sustainable availability of such treatments and endangers health, and may further deepen the issue of health equity. We call on Biogen to change this price.
Next, the access path turned to the Center for Medical Insurance and Medicaid Services (CMS). Like the FDA, we have great respect for CMS and how they will handle key future decisions. We are committed to working with them and the private payer community to expedite access to all those who might benefit from a successful clinical trial. In the context of medical insurance plans, CMS is facing a difficult decision on how to best achieve this goal, and we are ready to fully support CMS and private payers in this work for all communities in need.
Alzheimer’s Disease Association
The Alzheimer’s Association is leading the way to end Alzheimer’s and all other dementias by accelerating global research, promoting risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementias®.For more information, please visit www.alz.org Or call the 24/7 helpline 800.272.3900.
View original content and download multimedia:http://www.prnewswire.com/news-releases/alzheimers-association-statement-next-steps-for-new-alzheimers-treatment-301311251.html
SOURCE Alzheimer’s Association
[ad_2]
Source link
